Patents Represented by Attorney, Agent or Law Firm Reed & Associates
-
Patent number: 6500457Abstract: Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.Type: GrantFiled: August 14, 2000Date of Patent: December 31, 2002Assignee: Peirce Management, LLCInventors: Kamal K. Midha, Mark Hirsh, Whe-Yong Lo
-
Patent number: 6497173Abstract: An aggregate (10′) of pressure medium cylinders (11′, 12′) are used especially where there is required a relatively large length of stroke. At least a first (11′) and at least a second (12′) pressure medium cylinder are arranged by the side of each other with their longitudinal axes (11a, 11b) extending mutually parallel. The cylinder parts (13′, 14′) of the cylinders are rigidly connected to each other at least in pairs. Piston rods (17′, 18′) of said first and second cylinders are turned respectively in pairs in mutually opposite axial directions.Type: GrantFiled: November 22, 2000Date of Patent: December 24, 2002Inventor: Knut O. Dalland
-
Patent number: 6497904Abstract: Novel pharmaceutical formulations for treating a cellular proliferative disease are provided comprising: a therapeutically effective amount of a Golgi apparatus disturbing agent; a biocompatible carrier; and a solvent. In preferred formulations, the Golgi apparatus disturbing agent is brefeldin A (BFA) and the biocompatible carrier is a polymer such as chitin or chitosan. Methods of treating cellular proliferative diseases using the pharmaceutical formulations are also described.Type: GrantFiled: July 23, 2001Date of Patent: December 24, 2002Inventor: Saira Sayed Singh
-
Patent number: 6495663Abstract: Methods and compositions for transporting drugs and macromolecules across biological membranes are disclosed. In one embodiment, the invention includes a method for enhancing transport of a selected compound across a biological membrane, wherein a biological membrane is contacted with a conjugate containing a biologically active agent that is covalently attached to a transport polymer. In one embodiment, the polymer consists of from 6 to 25 subunits, at least 50% of which contain a guanidino or amidino sidechain moiety. The polymer is effective to impart to the attached agent a rate of trans-membrane transport across a biological membrane that is greater than the rate of trans-membrane transport of the agent in non-conjugated form.Type: GrantFiled: September 14, 1999Date of Patent: December 17, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jonathan B. Rothbard, Paul A. Wender
-
Patent number: 6495154Abstract: A method is provided for delaying the onset of ejaculation in an individual. The method involves systemic and on demand administration to an individual of a pharmaceutical formulation containing an amount of an active agent selected from the group consisting of clomipramine and pharmacologically acceptable acid addition salts thereof. Drug delivery may be accomplished via any route designed to provide systemic levels of the active agent effective to delay the onset of ejaculation. Pharmaceutical formulations and dosage forms are provided as well.Type: GrantFiled: November 21, 2000Date of Patent: December 17, 2002Assignee: Vivus Inc.Inventors: Peter Tam, Neil Gesundheit, Leland F. Wilson
-
Patent number: 6495127Abstract: The present invention relates generally to synthetic polymer compositions that form interpenetrating polymer networks. In a preferred embodiment, the compositions comprise two multifunctionally activated synthetic polymers, along with a tensile strength enhancer. Such compositions form matrices that exhibit superior cohesive strength and in many instances can serve as adequate replacements for surgical means of attaching tissues, such as sutures and medical staples.Type: GrantFiled: August 28, 2000Date of Patent: December 17, 2002Assignee: Cohesion Technologies, Inc.Inventors: Donald G. Wallace, George H. Chu, Jacqueline Anne Schroeder
-
Patent number: 6482179Abstract: Medical devices, and more particularly, devices, methods and compositions for sealing tissue puncture openings of patients after surgical operations are provided. A puncture wound sealing apparatus includes a positioning device having a depth sensing mechanism capable of providing feedback to an operator for the precise placement of an implant that is preferably resorbable and swellable after implantation. Such an implant provides for efficient sealing of the tissue puncture opening thus avoiding complications after surgical procedures in which blood vessels are punctured.Type: GrantFiled: May 24, 2000Date of Patent: November 19, 2002Assignee: Cohesion Technologies, Inc.Inventors: George H. Chu, Jeffrey E. Yeung, Frank A. DeLustro
-
Patent number: 6478980Abstract: The present invention features novel methods and compositions for coating textile substrates, wherein the coating compositions are composed of a coating agent selected from one of (a) an azetidinium polymer, (b) a guanidine polymer, (c) a mixture of an azetidinium polymer and a guanidine polymer, and (d) a copolymer of an azetidinium monomer and a guanidine monomer. Textile substrates coated with the compositions provide high quality printed images when printed with an ink containing a reactive dye having ionizable and/or nucleophilic groups capable of reacting with the coating agent in the textile coating composition. Images printed on a textile substrate coated with a coating composition of the invention are bleed-resistant, water-resistant (e.g., water-fast), detergent-resistant (e.g., detergent-fast), and/or are characterized by an enhanced chroma and hue.Type: GrantFiled: June 27, 2001Date of Patent: November 12, 2002Assignee: SRI InternationalInventor: Asutosh Nigam
-
Patent number: 6472434Abstract: Methods and formulations for minimizing excess collagen are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others.Type: GrantFiled: March 30, 2000Date of Patent: October 29, 2002Assignee: Vivus, Inc.Inventors: Virgil A. Place, Leland F. Wilson, Paul C. Doherty, Jr., Mark S. Hanamoto, Alfred P. Spivack, Neil Gesundheit, Sean R. Bennett
-
Patent number: 6472459Abstract: A method is provided for fabricating metallic microstructures, i.e., microcomponents of micron or submicron dimensions. A molding composition is prepared containing an optional binder and nanometer size (1 to 1000 nm in diameter) metallic particles. A mold, such as a lithographically patterned mold, preferably a LIGA or a negative photoresist mold, is filled with the molding composition and compressed. The resulting microstructures are then removed from the mold and the resulting metallic microstructures so provided are then sintered.Type: GrantFiled: January 16, 2001Date of Patent: October 29, 2002Assignee: Sandia CorporationInventors: Alfredo M. Morales, Michael R. Winter, Linda A. Domeier, Shawn M. Allan, Dawn M. Skala
-
Patent number: 6469016Abstract: Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.Type: GrantFiled: February 8, 2000Date of Patent: October 22, 2002Assignee: Vivus, Inc.Inventors: Virgil A. Place, Leland F. Wilson, Paul C. Doherty, Jr., Mark S. Hanamoto, Alfred P. Spivack, Neil Gesundheit, Sean R. Bennett
-
Patent number: 6468559Abstract: Oral dosage forms are provided for the administration of a bisphosphonic acid compound in the prevention and treatment of conditions involving calcium or phosphate metabolism, i.e., conditions associated with bone resorption such as osteoporosis, Paget's disease, periprosthetic bone loss, osteolysis, malignant hypercalcemia, metastatic bone disease, multiple myeloma, and periodontal disease. The dosage forms are either enterically coated capsules housing the drug in a liquid or semi-solid carrier, or enterically coated osmotically activated drug delivery devices.Type: GrantFiled: April 28, 2000Date of Patent: October 22, 2002Assignee: Lipocine, Inc.Inventors: Feng-Jing Chen, Mahesh V. Patel
-
Patent number: 6465175Abstract: Methods are provided for reducing background signals encountered in nucleic acid hybridization assays and other assays that involve hybridization of a labeled oligomer to its complement. The method is premised on the significant reduction of signal generation that occurs when a quenchable dye-labeled oligomer forms a hybrid complex. In addition, a method is provided for enhancing the detectable signal emitted from an amplification multimer hybridized to an oligomer probe to which a quenchable dye has been conjugated through a linker such that the emission from the dye is not quenched upon hybrid complex formation. Novel oligonucleotide probes are also provided that comprise an oligomer to which has been directly or indirectly through a linker a quenchable dye.Type: GrantFiled: September 3, 1998Date of Patent: October 15, 2002Assignee: Bayer CorporationInventors: Thomas Horn, Hartmut R. Schroeder, Brian D. Warner, Ellen Fiss, Todd Sells, Say-Jong Law
-
Patent number: 6458263Abstract: In the formation of multilevel LIGA microstructures, a preformed sheet of photoresist material, such as polymethylmethacrylate (PMMA) is patterned by exposure through a mask to radiation, such as X-rays, and developed using a developer to remove the exposed photoresist material. A first microstructure is then formed by electroplating metal into the areas from which the photoresist has been removed. Additional levels of microstructure are added to the initial microstructure by covering the first microstructure with a conductive polymer, machining the conductive polymer layer to reveal the surface of the first microstructure, sealing the conductive polymer and surface of the first microstructure with a metal layer, and then forming the second level of structure on top of the first level structure. In such a manner, multiple layers of microstructure can be built up to allow complex cantilevered microstructures to be formed.Type: GrantFiled: September 29, 2000Date of Patent: October 1, 2002Assignee: Sandia National LaboratoriesInventors: Alfredo Martin Morales, Linda A. Domeier
-
Patent number: 6458889Abstract: Crosslinkable compositions are provided that readily crosslink in situ to provide biocompatible, nonimmunogenic crosslinked biomaterials. The compositions contain at least three biocompatible, nonimmunogenic components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In a preferred embodiment, a first component is polynucleophilic, a second component is polyelectrophilic, and at least one third component contains one or more functional groups reactive with the nucleophilic moieties one the first or second component. At least one of the components is a polyfunctional hydrophilic polymer; the other components may also comprise hydrophilic polymers, or they may be low molecular weight, typically hydrophobic, crosslinkers. Methods for preparing and using the compositions are also provided.Type: GrantFiled: June 15, 2001Date of Patent: October 1, 2002Assignee: Cohesion Technologies, Inc.Inventors: Olof Mikael Trollsas, Donald G. Wallace, Frank A. DeLustro
-
Patent number: 6458383Abstract: A delayed release pharmaceutical dosage form for oral administration of a hydrophilic drug, e.g., a polysaccharide drug such as low molecular weight heparin, are provided. The dosage form comprises a composition of: (a) a therapeutically effective amount of low molecular weight heparin; (b) a bile salt or bile acid; (c) at least one surfactant selected from hydrophilic surfactants, lipophilic surfactants, and mixtures thereof; and a means for delaying release of the composition from the dosage form following oral administration. Osmotic drug delivery systems for oral administration of a hydrophilic drug are also provided, wherein an osmotically activated device houses the drug, a bile salt or bile acid, and at least one surfactant selected from the group consisting of hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. Methods for administering hydrophilic drugs, particularly polysaccharide drugs such as low molecular weight heparin, are also provided.Type: GrantFiled: December 29, 2000Date of Patent: October 1, 2002Assignee: Lipocine, Inc.Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fikstad
-
Patent number: 6455028Abstract: Pharmaceutical aerosol formulations are provided comprising substantially nonacicular particles of a bronchodilator selected from the group consisting of ipratropium and pharmacologically acceptable salts, solvates, hydrates, esters and isomers thereof. The described formulations include a propellant selected from the group consisting of a fluorocarbon propellant, a hydrogen-containing fluorocarbon propellant, and mixtures thereof. The formulations are substantially free of both surfactant and solvent. Methods of use and drug delivery devices are also provided.Type: GrantFiled: April 23, 2001Date of Patent: September 24, 2002Assignee: PharmascienceInventors: Harold Wulffhart, Khaldoun Ayoub, Rosemary Logiudice, Hanna Piskorz
-
Patent number: 6455517Abstract: Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.Type: GrantFiled: July 30, 2001Date of Patent: September 24, 2002Assignee: SRI InternationalInventors: Masato Tanabe, Richard H. Peters, Wan-Ru Chao, Ling Jong
-
Patent number: 6451339Abstract: The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.Type: GrantFiled: July 2, 2001Date of Patent: September 17, 2002Assignee: Lipocine, Inc.Inventors: Mahesh V. Patel, Feng-Jing Chen
-
Patent number: 6440426Abstract: An antigen-containing formulation is provided, comprising: (a) an antigen; (b) a TH1-inducing adjuvants; and (c) a sparingly soluble amino acid or a derivative thereof. The adjuvants may be, for example, monophosphoryl lipid A, 3′-de-O-acetylated monophosphoryl lipid A, derivatives thereof, or any other adjuvants that enhances an individual's TH response to the antigen. Suitable amino acids include tyrosine, tryptophan, derivatives thereof, and the like. Methods for using the formulation are also provided; in a particularly preferred embodiment, the formulation is used as a vaccine.Type: GrantFiled: September 17, 1999Date of Patent: August 27, 2002Assignee: Allergy Therapeutics LimitedInventors: Alan Wheeler, Anthony Berry